Literature DB >> 2392280

Refractive errors after cryotherapy in retinopathy of prematurity.

V Seiberth1, M C Knorz, R Trinkmann.   

Abstract

Because of acute retinopathy of prematurity 14 premature infants (900-1,630 g birth weight) were treated with cryocoagulation (10 children, both eyes; 4 only one eye) between 1976 and 1984 and were followed up until they were 2-7 years of age. The average refractive power of 20 eyes (those in which refraction could be determined) was -1.5 +/- 4.1 dptr. Twelve eyes (60.0%) were hyperopic (average: +1.3 +/- 0.4 dptr), and 8 eyes (40.0%) were myopic (average: -5.7 +/- 3.6 dptr). Three eyes in which cryocoagulation was done twice or three times because of a severe course developed pronounced myopia (greater than 7.0 dptr). When comparing both eyes of 4 children in whom cryotherapy had been carried out in only one eye, cryotherapy was found to have no influence on refractive errors (average anisometropia +0.4 +/- 0.4 dptr).

Entities:  

Mesh:

Year:  1990        PMID: 2392280     DOI: 10.1159/000310116

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  4 in total

1.  Cryotherapy and laser treatment for acute retinopathy of prematurity: refractive outcomes, a longitudinal study.

Authors:  F Laws; D Laws; D Clark
Journal:  Br J Ophthalmol       Date:  1997-01       Impact factor: 4.638

2.  Three year visual outcome for treated stage 3 retinopathy of prematurity: cryotherapy versus laser.

Authors:  I A Pearce; F C Pennie; L M Gannon; A M Weindling; D I Clark
Journal:  Br J Ophthalmol       Date:  1998-11       Impact factor: 4.638

3.  Refractive outcomes of three-port lens-sparing vitrectomy for retinopathy of prematurity (An AOS Thesis).

Authors:  Eric R Holz
Journal:  Trans Am Ophthalmol Soc       Date:  2009-12

4.  Refractive outcome following diode laser versus cryotherapy for eyes with retinopathy of prematurity.

Authors:  K Algawi; M Goggin; M O'Keefe
Journal:  Br J Ophthalmol       Date:  1994-08       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.